|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
40
|
May 13, 2025
|
|
Understanding Aqueous Nitrosation Kinetics of 4-Substituted Piperidines To Risk Assess Pharmaceutical Processes and Products-Pub
|
|
1
|
121
|
May 6, 2025
|
|
📅 Updates on Approaches to Acceptable Intakes of Nitrosamine Drug Substance Related Impurities (NDSRIs) and Bioequivalence Assessment for Reformulated Drug Products(CRCG)
|
|
39
|
3254
|
May 2, 2025
|
|
Autonomous CPCA Web-based calculator FREE
|
|
33
|
5885
|
April 30, 2025
|
|
N-nitroso-deucravacitinib
|
|
9
|
264
|
April 29, 2025
|
|
🕵🏻 OTC Market Withdrawal of Diphenhydramine
|
|
0
|
226
|
April 24, 2025
|
|
Visualization of Categorized Compounds by CPCA
|
|
67
|
8463
|
April 24, 2025
|
|
N-nitroso-esmolol
|
|
0
|
78
|
April 22, 2025
|
|
⁉️ Duloxetine Impurity NDSRI
|
|
9
|
868
|
April 22, 2025
|
|
The quagmire with the interim limit of nitroso duloxetine
|
|
6
|
523
|
April 21, 2025
|
|
N-nitrosamide carcinogenic effect
|
|
6
|
370
|
April 21, 2025
|
|
N- nitroso mebendazole
|
|
0
|
66
|
April 13, 2025
|
|
Primary amines in formation of nitrosamine
|
|
3
|
351
|
April 10, 2025
|
|
Clobam Nitrosamine Impurity
|
|
0
|
94
|
April 8, 2025
|
|
Risk mitigation based on DP specifications
|
|
10
|
589
|
April 7, 2025
|
|
:brazil: Lhasa Brazil Symposium: Aligning Pharma & Regulatory Standards Globally :brazil:
|
|
0
|
117
|
April 3, 2025
|
|
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential -Pub
|
|
8
|
505
|
April 2, 2025
|
|
Health Canada recalled drug products
|
|
0
|
637
|
April 1, 2025
|
|
Testing of N-nitroso-cinacalcet
|
|
5
|
414
|
March 27, 2025
|
|
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography–Tandem Mass Spectrometry and Structure–Activity Relationship Analysis -Pub
|
|
0
|
259
|
March 24, 2025
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
10
|
1258
|
March 21, 2025
|
|
AI limits and CPCA score (O=NN1CCN=C1CCl)
|
|
8
|
349
|
March 17, 2025
|
|
Analytical procedure development and proposed established conditions: A case study of a mass spectrometry based NDSRI analytical procedure -Pub
|
|
20
|
1927
|
March 12, 2025
|
|
Is there any possibility to generate the N-Desmethyl Tramadol in formulation?
|
|
5
|
440
|
March 11, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
27
|
2125
|
March 9, 2025
|
|
Nitrosamines et énantiomères
|
|
2
|
241
|
February 18, 2025
|
|
How to calculate the Limit of Nitrosamines from excipients?
|
|
5
|
603
|
February 4, 2025
|
|
What is CPCA Score for “N-nitroso of 3-Amino-1,2,4-triazole"
|
|
7
|
409
|
January 30, 2025
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
19
|
3291
|
April 23, 2025
|
|
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub
|
|
0
|
454
|
January 29, 2025
|